NasdaqCM - Nasdaq Real Time Price USD

BioNexus Gene Lab Corp. (BGLC)

0.5801 -0.0194 (-3.24%)
At close: May 13 at 4:00 PM EDT
0.6100 +0.03 (+5.15%)
After hours: May 13 at 7:17 PM EDT
Loading Chart for BGLC
DELL
  • Previous Close 0.5995
  • Open 0.5800
  • Bid 0.4135 x 200
  • Ask 0.7543 x 200
  • Day's Range 0.5800 - 0.5999
  • 52 Week Range 0.0800 - 9.4900
  • Volume 57,000
  • Avg. Volume 277,152
  • Market Cap (intraday) 10.249M
  • Beta (5Y Monthly) 1.95
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1800
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

www.bionexusgenelab.com

30

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BGLC

Performance Overview: BGLC

Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BGLC
9.45%
S&P 500
9.47%

1-Year Return

BGLC
75.79%
S&P 500
26.61%

3-Year Return

BGLC
68.64%
S&P 500
28.51%

5-Year Return

BGLC
--
S&P 500
36.52%

Compare To: BGLC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BGLC

Valuation Measures

Annual
As of 5/13/2024
  • Market Cap

    10.25M

  • Enterprise Value

    4.45M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.94

  • Price/Book (mrq)

    1.06

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -26.91%

  • Return on Assets (ttm)

    -12.68%

  • Return on Equity (ttm)

    -32.21%

  • Revenue (ttm)

    9.77M

  • Net Income Avi to Common (ttm)

    -2.63M

  • Diluted EPS (ttm)

    -0.1800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.93M

  • Total Debt/Equity (mrq)

    1.52%

  • Levered Free Cash Flow (ttm)

    566.75k

Research Analysis: BGLC

Company Insights: BGLC

Research Reports: BGLC

People Also Watch